Results 51 to 60 of about 273,405 (257)
Transcatheter treatment for tricuspid valve disease. [PDF]
Approximately 4% of subjects aged 75 years or more have clinically relevant tricuspid regurgitation (TR). Primary TR results from anatomical abnormality of the tricuspid valve apparatus and is observed in only 8-10% of the patients with tricuspid valve ...
Maisano, Francesco +27 more
core +2 more sources
Successful Percutaneous Retrieval of an Embolized MitraClip From the Right Subclavian Artery
ABSTRACT Single leaflet device attachment (SLDA) after mitral transcatheter valve edge‐to‐edge repair (M‐TEER) has been reported in up to 5% of patients. However, complete embolization of the M‐TEER device is exceedingly rare. Device retrievals in all previously reported cases were completed by vascular surgery cut down at the end. In this case, we are
Seyed Hossein Aalaei‐Andabili +2 more
wiley +1 more source
Multimodality Imaging in the Management of Tricuspid Valve Regurgitation [PDF]
Approximately 5% of elderly patients suffer from moderate or severe tricuspid valve regurgitation, which is an independent predictor of high morbidity and mortality.
Brugger, Nicolas +8 more
core +2 more sources
Reoperation for isolated rheumatic tricuspid regurgitation
Background The reoperation for isolated tricuspid regurgitation in rheumatic population is rare and still unclear and controversial because of the rarity of publications.
Younes Moutakiallah +8 more
doaj +1 more source
ABSTRACT The case regards a 73‐year‐old male who was referred for consideration of percutaneous left atrial appendage closure. His left atrial appendage was ligated during prior mitral valve surgery, but was noted to be patent on a recent transesophageal echocardiography. An Amulet device was selected based on CT planning.
Zach Rozenbaum, Eric Gnall
wiley +1 more source
Tricuspid stenosis is a rare condition, whereas tricuspid regurgitation is more frequent, especially in its secondary form. For appropriate management, secondary tricuspid regurgitation has to be clearly distinguished from primary tricuspid regurgitation.
Michele De Bonis, Patrizio Lancellotti
core +1 more source
Early Experience With Evoque Transcatheter Tricuspid Valve Replacement in Carcinoid Heart Disease
ABSTRACT Tricuspid regurgitation (TR) is nearly universal in carcinoid heart disease (CHD), but surgical replacement carries significant risk, and CHD was excluded from the landmark TRISCEND II trial. We present seven patients with CHD undergoing Evoque transcatheter tricuspid valve replacement (TTVR) at two tertiary centers.
Jackson S. Burton +3 more
wiley +1 more source
Primary tricuspid valve regurgitation may be encountered in daily practice as a result of multiple etiologies. Described herein are the cases of 2 patients with severe primary tricuspid regurgitation.
Münevver Sarı +4 more
doaj +1 more source
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
Perinatal mortality remains high among fetuses diagnosed with Ebstein's anomaly of the tricuspid valve. The subgroup of patients with pulmonary valve regurgitation is at particularly high risk.
Alisa Arunamata +5 more
doaj +1 more source

